Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A Randomized Trial - Université de Lorraine Access content directly
Journal Articles Gastroenterology Year : 2013

Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A Randomized Trial

Fred F. Poordad (1) , Eric Lawitz (1) , K. Rajender Reddy (2) , Nezam Afdhal (3) , Christophe Hézode (4) , Stefan Zeuzem (5) , Samuel Lee (6) , Jose Luis Calleja (7) , Robert Brown (8) , Antonio Craxi (9) , Heiner Wedemeyer (10) , L. M. Nyberg (11) , David R. Nelson (12) , Lorenzo Rossaro (13) , Luis Balart (14) , Timothy R. Morgan (15) , Bruce R. Bacon (16) , Steven L. Flamm (17) , Kris V. Kowdley (18) , Weiping Deng (19) , Kenneth J. Koury (19) , Lisa D. Pedicone (19) , Frank J. Dutko (19) , Margaret H. Burroughs (19) , Katia Alves (19) , Janice Wahl (19) , Clifford A. Brass (19) , Janice K. Albrecht (19) , Mark S. Sulkowski (20) , R. Bailey , C. Cooper , S.V. Feinman , P. Marotta , E. Tam , F. Wong , Marc Bourlière , Jean-Pierre Bronowicki (21) , Christophe Hezode , A. Tran , Tobias Goeser , D. Klass , R. Schmid , M. Pirisi , M. Zuin , M. Bennett , D. Bernstein , T. Box , T. Boyer , D. Clain , J. Crippin , M. Davis , Franco Felizarta , Bradley Freilich , Joseph Galati , G. Galler , Reem Ghalib , A. Gibas , E. Godofsky , F. Gordon , S. Gordon , J. Gross , S. Harrison , J. Herrera , S. Herrine , R. Herring , I. Jacobson , S. Joshi , A. Kilby , J. King , A. Koch , Kris V Kowdley , P. Kwo , E. Lebovics , W. Lee , J. Levin , Xiaojian Li , Velimir Luketic , M. Mailliard , Jonathan Mccone , D. Mikolich , A. Muir , K. Mullen , F. Nunes , A. Nyberg , P. Pandya , M. Pauly , C. Peine , Gary Poleynard , J. Poulos , D. Pound , M. Rabinovitz , Natarajan Ravendhran , R. Reddy , Robert Reindollar , A. Reuben , T. Riley , R. Rubin , M. Russo , M. Ryan , S. Saab , J. Santoro , W. Schmidt , T. Sepe , K. Sherman , Marketa Sjögren , J. Slim , C. Smith , L. Stein , R. Strauss , H. Vargas , John Vierling , D. Witt , G. Wu , Z. Younes
Eric Lawitz
  • Function : Author
  • PersonId : 1027564
Samuel Lee
  • Function : Author
Robert Brown
L. M. Nyberg
  • Function : Author
Weiping Deng
  • Function : Author
Kenneth J. Koury
  • Function : Author
Lisa D. Pedicone
  • Function : Author
Frank J. Dutko
  • Function : Author
Katia Alves
  • Function : Author
Janice Wahl
  • Function : Author
Clifford A. Brass
  • Function : Author
  • PersonId : 940979
R. Bailey
  • Function : Author
C. Cooper
  • Function : Author
S.V. Feinman
  • Function : Author
P. Marotta
  • Function : Author
E. Tam
  • Function : Author
F. Wong
  • Function : Author
Marc Bourlière
  • Function : Author
  • PersonId : 900179
Christophe Hezode
  • Function : Author
  • PersonId : 881467
A. Tran
  • Function : Author
Tobias Goeser
  • Function : Author
D. Klass
  • Function : Author
R. Schmid
  • Function : Author
M. Pirisi
  • Function : Author
M. Zuin
  • Function : Author
M. Bennett
  • Function : Author
D. Bernstein
  • Function : Author
T. Box
  • Function : Author
T. Boyer
  • Function : Author
D. Clain
  • Function : Author
J. Crippin
  • Function : Author
M. Davis
  • Function : Author
Franco Felizarta
  • Function : Author
Bradley Freilich
  • Function : Author
Joseph Galati
  • Function : Author
G. Galler
  • Function : Author
Reem Ghalib
  • Function : Author
A. Gibas
  • Function : Author
E. Godofsky
  • Function : Author
F. Gordon
  • Function : Author
S. Gordon
  • Function : Author
J. Gross
  • Function : Author
S. Harrison
  • Function : Author
J. Herrera
S. Herrine
  • Function : Author
R. Herring
  • Function : Author
I. Jacobson
  • Function : Author
S. Joshi
  • Function : Author
A. Kilby
  • Function : Author
J. King
  • Function : Author
A. Koch
  • Function : Author
Kris V Kowdley
  • Function : Author
P. Kwo
  • Function : Author
E. Lebovics
  • Function : Author
W. Lee
  • Function : Author
J. Levin
  • Function : Author
Xiaojian Li
  • Function : Author
Velimir Luketic
  • Function : Author
M. Mailliard
  • Function : Author
Jonathan Mccone
  • Function : Author
D. Mikolich
  • Function : Author
A. Muir
  • Function : Author
K. Mullen
  • Function : Author
F. Nunes
  • Function : Author
A. Nyberg
  • Function : Author
P. Pandya
  • Function : Author
M. Pauly
  • Function : Author
C. Peine
  • Function : Author
Gary Poleynard
  • Function : Author
J. Poulos
  • Function : Author
D. Pound
  • Function : Author
M. Rabinovitz
  • Function : Author
Natarajan Ravendhran
  • Function : Author
R. Reddy
  • Function : Author
Robert Reindollar
  • Function : Author
A. Reuben
  • Function : Author
T. Riley
  • Function : Author
R. Rubin
  • Function : Author
M. Russo
  • Function : Author
M. Ryan
  • Function : Author
S. Saab
  • Function : Author
J. Santoro
  • Function : Author
W. Schmidt
  • Function : Author
T. Sepe
  • Function : Author
K. Sherman
  • Function : Author
Marketa Sjögren
  • Function : Author
J. Slim
  • Function : Author
C. Smith
L. Stein
  • Function : Author
R. Strauss
  • Function : Author
H. Vargas
  • Function : Author
John Vierling
  • Function : Author
D. Witt
  • Function : Author
G. Wu
  • Function : Author
Z. Younes
  • Function : Author

Abstract

Background & Aims Treatment of hepatitis C virus (HCV) infection with boceprevir, peginterferon, and ribavirin can lead to anemia, which has been managed by reducing ribavirin dose and/or erythropoietin therapy. We assessed the effects of these anemia management strategies on rates of sustained virologic response (SVR) and safety. Methods Patients (n = 687) received 4 weeks of peginterferon and ribavirin followed by 24 or 44 weeks of boceprevir (800 mg, 3 times each day) plus peginterferon and ribavirin. Patients who became anemic (levels of hemoglobin approximately ≤10 g/dL) during the study treatment period (n = 500) were assigned to groups that were managed by ribavirin dosage reduction (n = 249) or erythropoietin therapy (n = 251). Results Rates of SVR were comparable between patients whose anemia was managed by ribavirin dosage reduction (71.5%) vs erythropoietin therapy (70.9%), regardless of the timing of the first intervention to manage anemia or the magnitude of ribavirin dosage reduction. There was a threshold for the effect on rate of SVR: patients who received <50% of the total milligrams of ribavirin assigned by the protocol had a significantly lower rate of SVR (P < .0001) than those who received ≥50%. Among patients who did not develop anemia, the rate of SVR was 40.1%. Eleven thromboembolic adverse events were reported in 9 of 295 patients who received erythropoietin, compared with 1 of 392 patients who did not receive erythropoietin. Conclusions Reduction of ribavirin dosage can be the primary approach for management of anemia in patients receiving peginterferon, ribavirin, and boceprevir for HCV infection. Reduction in ribavirin dosage throughout the course of triple therapy does not affect rates of SVR. However, it is important that the patient receives at least 50% of the total amount (milligrams) of ribavirin assigned by response-guided therapy.
No file

Dates and versions

hal-01707324 , version 1 (12-02-2018)

Identifiers

Cite

Fred F. Poordad, Eric Lawitz, K. Rajender Reddy, Nezam Afdhal, Christophe Hézode, et al.. Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A Randomized Trial. Gastroenterology, 2013, 145 (5), pp.1035 - 1044.e5. ⟨10.1053/j.gastro.2013.07.051⟩. ⟨hal-01707324⟩
23 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More